Published in BMC Microbiol on March 28, 2007
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood. J Clin Microbiol (2012) 0.99
Application of molecular diagnostic techniques for viral testing. Open Virol J (2012) 0.81
Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye. Virol J (2010) 0.81
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
Real-time PCR for mRNA quantitation. Biotechniques (2005) 7.80
A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn (2001) 3.10
Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol (1999) 2.95
Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene (2003) 2.72
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet (2003) 1.70
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res (2000) 1.42
Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res (2003) 1.39
Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol (2002) 1.34
Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation (2001) 1.32
Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol (1996) 1.28
Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis (2001) 1.22
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res (2006) 1.19
A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res (2005) 1.14
Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. J Clin Virol (2004) 1.03
Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol (2001) 1.01
Comparison of commercial real-time PCR assays for quantification of Epstein-Barr virus DNA. J Clin Microbiol (2005) 0.98
Real-time quantitative PCR of Epstein-Barr virus BZLF1 DNA using the LightCycler. J Virol Methods (2003) 0.90
Persistence of human T cell lymphotropic virus type 1 (HTLV-1) sequences in peripheral blood mononuclear cells from patients with mycosis fungoides. J Exp Med (1994) 0.88
Evaluation of a commercial real-time PCR assay for quantitation of Epstein-Barr virus DNA in different groups of patients. J Virol Methods (2006) 0.85
Comparison of a LightCycler-based real-time PCR for quantitation of Epstein-Barr viral load in different clinical specimens with semiquantitative PCR. J Med Virol (2006) 0.78
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One (2010) 1.33
Urinary tract infections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens. Med Sci Monit (2007) 1.24
Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol (2006) 1.22
Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol (2011) 1.04
Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays. J Clin Microbiol (2011) 1.03
Fatal disseminated toxoplasmosis during primary HIV infection. Curr HIV Res (2007) 1.02
The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. J Immunol (2005) 0.96
Evaluation of a real-time polymerase chain reaction assay for the laboratory diagnosis of giardiasis. Diagn Microbiol Infect Dis (2009) 0.95
Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for Human Cytomegalovirus (HCMV) management in immunocompromised patients. BMC Infect Dis (2007) 0.94
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther (2008) 0.93
Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. New Microbiol (2011) 0.90
Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother (2012) 0.87
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis. J Med Virol (2008) 0.86
Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin Endocrinol (Oxf) (2004) 0.85
Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J (2004) 0.85
Screening and Management of HIV-2-Infected Individuals in Northern Italy. AIDS Patient Care STDS (2008) 0.84
Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis (2005) 0.84
HIV infection among illegal migrants, Italy, 2004-2007. Emerg Infect Dis (2009) 0.83
Polymerase chain reaction as a rapid diagnostic tool for therapy of acute retinal necrosis syndrome. J Med Virol (2003) 0.83
Transmission of SEN virus from mothers to their babies. J Med Virol (2002) 0.82
Bacterial species present in the lower male genital tract: a five-year retrospective study. Eur J Contracept Reprod Health Care (2010) 0.82
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals. Curr HIV Res (2008) 0.81
Performance evaluation of the automated NucliSens easyMAG nucleic acid extraction platform in comparison with QIAamp Mini kit from clinical specimens. Diagn Microbiol Infect Dis (2009) 0.81
HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4(+) T cells. Virus Res (2007) 0.81
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. AIDS Patient Care STDS (2007) 0.81
Recent increase in enterococci, viridans streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis (2010) 0.80
Real-time quantitation of hepatitis B virus (HBV) DNA in tumorous and surrounding tissue from patients with hepatocellular carcinoma. J Med Virol (2002) 0.80
Determination of HCV genotype by direct sequence analysis of quantitative PCR products. J Med Virol (2003) 0.80
Evaluation of a real-time polymerase chain reaction assay for the detection of Dientamoeba fragilis. Diagn Microbiol Infect Dis (2010) 0.80
Immune-mediated hepatitis-associated aplastic anemia caused by the emergence of a mutant hepatitis B virus undetectable by standard assays. J Hepatol (2007) 0.80
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents (2006) 0.79
A system consisting of cation-exchange chromatography, combined surface-activated chemical and electrospray ionization, and ion-trap analysis for the analysis of 8-oxo-7,8-dihydro-2'-deoxyguanosine in urine. Rapid Commun Mass Spectrom (2012) 0.78
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol (2005) 0.78
Prevaccination distribution of human papillomavirus types in Italian women with high-risk lesions and cervical neoplasia. Intervirology (2010) 0.78
Rapid detection and identification of Brachyspira aalborgi from rectal biopsies and faeces of a patient. Res Microbiol (2003) 0.77
A serially coupled stationary phase method for the determination of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine by liquid chromatography ion trap tandem mass spectrometry. Redox Biol (2013) 0.75
[Analytical quality in biological monitoring of workers exposed to chemicals: experience of the Prevention and Safety at the Workplace Service in Modena]. Med Lav (2010) 0.75
Long-term stability of serum samples positive for carbohydrate deficient transferrin (CDT) routinely stored at -20 °C. Clin Chem Lab Med (2016) 0.75
Mycobacterium szulgai identification by hsp65 gene sequencing in an HIV-positive patient with non-Hodgkin's lymphoma. New Microbiol (2006) 0.75
Vitamin D, atopy, immunity. Clin Chem Lab Med (2014) 0.75
Evaluation of INNO-LiPA assay for direct detection of mycobacteria in pulmonary and extrapulmonary specimens. New Microbiol (2006) 0.75
Impact of detectable human cytomegalovirus DNAemia on viro-immunological effectiveness of HAART in HIV-infected patients naive to antiretroviral therapy. New Microbiol (2012) 0.75
Bacteria enclosure between silica-coated membranes for the degradation of organic compounds in contaminated water. Water Res (2005) 0.75
Effectiveness of the biological monitoring of chemical exposure in the workplace: results of a survey in an area of Northern Italy. Int J Hyg Environ Health (2010) 0.75